122 related articles for article (PubMed ID: 15524495)
1. Treatment of rheumatoid arthritis with biologic DMARDS (Rituximab and Etanercept).
Gashi AA; Rexhepi S; Berisha I; Kryeziu A; Ismaili J; Krasniqi G
Med Arch; 2014; 68(1):51-3. PubMed ID: 24783914
[TBL] [Abstract][Full Text] [Related]
2. Etanercept (Enbrel
Shannon E; Daffy J; Jones H; Paulson A; Vicik SM
Clin Pharmacol; 2017; 9():87-99. PubMed ID: 28790869
[TBL] [Abstract][Full Text] [Related]
3. Identifying therapeutic alternatives in Medicare drug price negotiation: The case of etanercept.
Mooney H; Martin M; Bendicksen L; Kesselheim AS; Rome BN; Lalani HS
J Manag Care Spec Pharm; 2024 Mar; 30(3):226-233. PubMed ID: 38088900
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.
Diamantopoulos A; Finckh A; Huizinga T; Sungher DK; Sawyer L; Neto D; Dejonckheere F
Pharmacoeconomics; 2014 Aug; 32(8):775-87. PubMed ID: 24854959
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients.
Borrás-Blasco J; Gracia-Pérez A; Rosique-Robles JD; Casterá ME; Abad FJ
Expert Opin Biol Ther; 2014 Feb; 14(2):145-50. PubMed ID: 24359492
[TBL] [Abstract][Full Text] [Related]
6. Research trends in contemporary health economics: a scientometric analysis on collective content of specialty journals.
Zwack CC; Haghani M; de Bekker-Grob EW
Health Econ Rev; 2024 Jan; 14(1):6. PubMed ID: 38270771
[TBL] [Abstract][Full Text] [Related]
7. Preventing drug coverage disruption for enrollees in the replacement drug demo.
Yeske-Amato S; White B
Biotechnol Healthc; 2005 Feb; 2(2):24-7. PubMed ID: 23393447
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.
Russell A; Beresniak A; Bessette L; Haraoui B; Rahman P; Thorne C; Maclean R; Dupont D
Clin Rheumatol; 2009 Apr; 28(4):403-12. PubMed ID: 19089488
[TBL] [Abstract][Full Text] [Related]
9. N-of-1 trials of expensive biological therapies: a third way?
Kravitz RL; Duan N; White RH
Arch Intern Med; 2008 May; 168(10):1030-3. PubMed ID: 18504330
[TBL] [Abstract][Full Text] [Related]
10. The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis.
Sørensen J; Andersen LS
Pharmacoeconomics; 2005; 23(3):289-98. PubMed ID: 15836009
[TBL] [Abstract][Full Text] [Related]
11. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
Lyseng-Williamson KA; Foster RH
Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
Spalding JR; Hay J
Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
[TBL] [Abstract][Full Text] [Related]
13. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
Tanno M; Nakamura I; Ito K; Tanaka H; Ohta H; Kobayashi M; Tachihara A; Nagashima M; Yoshino S; Nakajima A
Mod Rheumatol; 2006; 16(2):77-84. PubMed ID: 16633926
[TBL] [Abstract][Full Text] [Related]
14. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
Doan QV; Chiou CF; Dubois RW
J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801
[TBL] [Abstract][Full Text] [Related]
15. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2004; 22(16):1071-95. PubMed ID: 15524495
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
